Table 5.
Institution | Regimen | Setting | Trial description | Status | Trial ID |
---|---|---|---|---|---|
UTHSCSA | Sirolimus | Neoadjuvant | Phase 0 trial for preoperative treatment. Tissue evaluated before and after treatment. | Recruiting | NCT01827618 |
Hoosier oncology group | Everolimus +/− Paclitaxel | Unspecified^ | Phase II trial for Cisplatin ineligible patients. Not a perioperative specific study. | Recruiting | NCT01215136 |
University of Washington | Sirolimus + GC | Unspecified^ | Phase I/II trial for disease of any stage. Patients likely will undergo cystectomy. | Ongoing | NCT01938573 |
MDACC | INF-alpha | Prior to Biopsy | Phase 1 trial with TURBT conducted following treatment. Radical cystectomy may follow. | Ongoing | NCT00082719 |
GC = Gemcitabine + Cisplatin. UTHSCSA = The University of Texas Health Science Center at San Antonio. MDACC = M.D. Anderson Cancer Center. TURBT = Transurethral Resection of Bladder Tumor.
*Table does not include trials for multiple solid tumors that may include bladder cancer as a subset.
^Unspecified regimens can be given in the neoadjuvant, adjuvant, locally recurrent, or metastatic setting.